

MilliporeSigma advances next generation antibody-drug conjugate therapies

29 October 2021 | News

MilliporeSigma's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges

MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has announced that its Life Science business sector has launched new technology and expanded capacity to advance antibody-drug conjugate (ADC) therapies.

These initiatives underscore MilliporeSigma's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future.

With the launch of its ChetoSensar™ technology, MilliporeSigma is one of the front runners working to address the hydrophobicity of ADCs, in tandem with its CDMO services.

In addition, the company will enhance the ADC capabilities of its clinical manufacturing facility in St. Louis, Missouri, US in December. This facility will provide larger footprint to enable large-scale production including chromatographic purification for early phase clinical supply.